Schizophrenia

Neurocrine Biosciences and Sosei Group Corporation have announced a partnership to create a new brand of protein inhibitor that the former plans to study to improve treatments for a wide range of neuropsychiatric disorders.

Paliperidone palmitate appeared to benefit Black patients with recent-onset schizophrenia or schizophreniform disorder, according to study results presented at NEI Congress.

Prescription opioid dispensing decreased for patients with schizophrenia, as well as those with bipolar disorder, between 2015 and 2019, according to study results presented at NEI Congress.

A digital medicine system appeared to improve clinical schizophrenia symptoms beyond the effects of oral pharmacotherapy alone, according to study results presented at Psych Congress.

The FDA can require a safety program called a Risk Evaluation and Mitigation Strategy, or REMS, for a medication with serious safety concerns to ensure the benefits outweigh the risks. An REMS is designed to reinforce behaviors and actions that support safe use of that medication to mitigate a specific risk.

Schizophrenia’s approximate societal burden was $341.5 billion in the U.S. in 2019, according to study results presented at Psych Congress.

Patients with severe mental illness, particularly those with schizophrenia who are insured by Medicaid, have significant social risk factors that may adversely affect overall health, according to a study presented at Psych Congress.

Healio Psychiatry’s five most-viewed stories in October highlight: the mental health effects of sibling bullying, the link between staying up late and suicidal thoughts, and regulatory developments.

Alkermes has announced that its schizophrenia/bipolar 1 disorder treatment Lybalvi is now available by prescription in the U.S.

Otsuka and Lundbeck have announced FDA acceptance of a supplemental new drug application for Rexulti for the treatment of schizophrenia in adolescents.